ClinicalTrials.gg
CompletedNCT05747820EVOLUTIONUpdated Feb 13, 2024

Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure

An observational study in Heart Failure and Heart Decompensation, sponsored by Corteria Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Corteria Pharmaceuticals · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
42
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This observational study is conducted to assess the evolution of multiple markers of congestion over 4 weeks after a worsening heart failure (WHF) event treated in an outpatient unit

Read the detailed description

This is a multicenter, non-randomized, observational study designed to assess the evolution of multiple markers (physical, echocardiographic, and biomarkers) of congestion in 40 patients with chronic heart failure (CHF) treated over 4 weeks with 40 to 120 mg daily oral furosemide after an event of WHF treated in an outpatient unit. Patients at selected centers may participate in a telemetry ancillary study, in which real-time, continuous, non-invasive measurements of physiologic parameters of heart failure will be obtained through use of a wearable medical telemetry device.

Approximately 40 patients with CHF with reduced or mildly reduced left ventricular ejection fraction (EF \< 50%) who had an admission for WHF in the preceding 1-12 months and who develop symptoms of WHF over the week before presentation to an outpatient clinic will be enrolled. Patients will attend five outpatient visits over the course of 4 weeks.

At each visit, the patient's vital signs will be measured, clinical assessments (NYHA class, jugular vein distension, peripheral edema score, pulmonary rales) will be performed, and blood samples for central assays will be obtained. Detailed echocardiographic examination will be performed prior to enrolment in the first visit and at Visit 5.

Biomarkers related to cardiac and renal function will be measured in blood and urine samples at each visit.

02

Conditions studied

  • Heart Failure
  • Heart Decompensation

Browse trials for

Keywords

  • Worsening Heart Failure
03

In context

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's enrollment of 42 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Corteria Pharmaceuticals is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Approximately 40 adult male and female patients with a diagnosis of HFrEF (EF\<40%) and HFmrEF (EF >40 \< 50%) who had a hospital admission for HF within 1 to12 months prior to screening and developed worsening symptoms of HF during the week prior to presentation to an outpatient clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 and \< 80 years of age.
  2. Previous documented hospital admission for HF between 12 months and 1 month prior to Screening.
  3. Ambulatory patients with a diagnosis of stable class II - III HF with \<50%, who experience a worsening of heart failure (WHF), with worsening signs and/or symptoms of heart failure requiring institution or up titration of loop diuretic therapy, in the week preceding their visit to the outpatient HF clinic and with at the time of Screening:

    1. Dyspnea and at least one symptom of congestion (rales, orthopnea, peripheral oedema)
    2. Imaging confirmation of congestion as defined by either pulmonary congestion on chest X-ray or at least 2 B-lines by lung ultrasound.
  4. Stable oral doses of ACEi, ARB or ARNi, beta-blocker, mineralocorticoid antagonist (MRA), and SGLT2i for > 1 month prior to screening.
  5. An increase in the prescribed oral loop diuretic dose up to 120 mg daily furosemide or equivalent*for the treatment of the WHF event.
  6. Biomarker profile suggestive of significant HF inclusive of NT-proBNP ≥1500 pg/ml, and elevated TnT from 15 ng/L (0.015 mcg/L) to 150 ng/L (0.15 mcg/L) or equivalent TnI using ultrasensitive assay.
  7. Mild to moderate renal impairment ( by the simplified MDRD formula of >30 and \<60 ml/min/1.73 m2).
  8. Written to participate in the study.
  9. Ability to comply with all study requirements, without major morbidities compromising the patient's ability to participate and understand the study for 90 days.

Exclusion criteria

Exclusion Criteria:

  1. Significant pulmonary disease contributing substantially to the patients' dyspnea such as \< 1 liter or need for chronic therapy.
  2. Myocardial infarction, unstable angina, ICD or CRT implantation, or cardiac surgery, including percutaneous transluminal coronary intervention, within past 3 months.
  3. History of heart transplant or on a transplant list or using or planned to be implanted with a ventricular assist device.
  4. Significant uncontrolled arrythmia such as atrial fibrillation with a persistent heart rate > 120 beast/minute, any bradyarrhythmia with a persistent heart rate \< 50 beats/min, sustained supraventricular tachycardia, any evidence of tri-fascicular block by .
  5. Sustained ventricular arrhythmia with syncopal episodes within past 3 months that is untreated.
  6. Presence of any hemodynamically moderate or severe valvular stenosis or regurgitation, except for moderate mitral or tricuspid regurgitation secondary to left ventricular dilatation. Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract.
  7. Stroke or within the past 3 months.
  8. Primary or alcoholic liver disease considered to be life threatening.
  9. Any episode of symptomatic hypotension within 3 months prior to screening.
  10. Coagulation or bleeding disorder.
  11. Systolic blood pressure \< 100 mmHg or >180 mmHg.
  12. Serum sodium > 146 mEq/L (146 mmol/L) or \<135 mEq/L
  13. Serum potassium > 5.2 mEq/L (5.2 mmol/L) or \< 3.5 mEq/L (3.5 mmol/ L).
  14. Ultrafiltration or dialysis within 3 months prior to Screening.
  15. to furosemide.
  16. History or presence of any other diseases (i.e. including ) with a of \< 3 months.
  17. Participation in any CHF trial or any drug or device study within the 30 days prior to Screening.
  18. History of noncompliance to medical regimens and patients who are considered potentially unreliable.
  19. Pregnant or nursing (lactating) women.
  20. Active infection based on abnormal temperature and/or elevated WBC count.
  21. Any evidence of COVID -19 infection
  22. \<8 g/L or receipt of blood transfusion within 3 months prior to Screening.
  23. to the use of the wrist-worn telemetry device: skin problem or wound in the wrist area, inclusive of tattoos.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
42 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherObservational study

    This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit

06

What researchers measure

Primary outcomes

  1. Change in E/e' ratio

    Change in E/e' ratio, measured on echocardiography

    Time frame: Screening (Visit 1) and week 4 (beginning of Visit 5).

  2. Changes in Left Ventricular End-Diastolic Diameter (LVEDD)

    Changes in LVEDD measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  3. Changes in Left Ventricular End-Systolic Diameter (LVESD)

    Changes in LVESD measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  4. Changes in Left Ventricular End-Diastolic Volume (LVEDV)

    Changes in LVEDV measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  5. Changes in Left Ventricular End-Systolic Volume (LVESV)

    Changes in LVESV measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  6. Changes in Left Ventricular Ejection Fraction (LVEF)

    Changes in LVEF measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  7. Changes in mitral E-velocity

    Changes in mitral E-velocity measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  8. Changes in mitral A-velocity

    Changes in mitral A-velocity measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  9. Changes in E' velocity

    Changes in E' velocity measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  10. Changes in Right Ventricular Systolic Pressure (RVSP)

    Changes in RVSP measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  11. Changes in Tricuspid Annular Pulmonary Systolic Excursion (TAPSE)

    Changes in TAPSE measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  12. Changes in S' velocity

    Changes in S' velocity measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  13. Changes in Inferior Vena Cava (IVC) diameter

    Changes in IVC (minimum and maximum) measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  14. Changes in Left Atrium (LA) surface

    Changes in LA surface measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  15. Changes in Right Atrium (RA) surface

    Changes in RA surface measured on echocardiography from screening to Week 4

    Time frame: From screening to 4 weeks

  16. Changes in patient-reported dyspnea

    Weekly changes in patient-reported dyspnea

    Time frame: From screening to 4 weeks

  17. Changes in clinically-assessed jugular venous pulse

    Weekly changes in clinically-assessed jugular venous pulse

    Time frame: From screening to 4 weeks

  18. Changes in clinically-assessed peripheral edema

    Weekly changes in peripheral edema

    Time frame: From screening to 4 weeks

  19. Changes in estimated Glomerular Filtration Rate (eGFR)

    Changes in eGFR between screening, Week 2 and Week 4 visit.

    Time frame: From screening to 4 weeks

  20. Changes in serum creatinine

    Changes in serum creatinine between screening, Week 2 and Week 4 visit.

    Time frame: From screening to 4 weeks

  21. Changes in NT-proBNP

    Changes in NTproBNP between screening, Week 2 and Week 4 visit.

    Time frame: From screening to 4 weeks

  22. Changes in high sensitivity Troponin T (HsTnT)

    Changes in HsTnT between screening, Week 2 and Week 4 visit.

    Time frame: From screening to 4 weeks

  23. Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ)-12

    Changes in KCCQ-12 inclusive of total symptoms score and sub scores from screening to Week 4

    Time frame: From screening to 4 weeks

  24. Weekly changes in telemetered parameters in patients wearing the wrist-worn device (Philips Health Band)

    Weekly changes in activity in those patients wearing the wrist-worn device (Philips Health Band)

    Time frame: From screening to 4 weeks

07

Study locations

4 sites
  • Institute of Cardiology Levon Hovhannisyan
    Yerevan, 0014, Armenia
  • Erebuni Medical Center
    Yerevan, 0087, Armenia
  • Health Institution Medico Laser, Cardiology ward
    Banja Luka, 78000, Bosnia and Herzegovina
  • Universty Clinical Hospital Mostar, Clinic for Internal diseases with dyalisis center, Clinical ward for cardiology
    Mostar, 88000, Bosnia and Herzegovina
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Apr 2023, 6 months.

Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's 6 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Feb 28, 2023
StartActual
Sep 28, 2022
Primary completionActual
Apr 27, 2023
CompletionActual
Apr 27, 2023
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05747820
Lead sponsor
Corteria Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 28, 2023
Start date
Sep 28, 2022
Primary completion
Apr 27, 2023
Completion
Apr 27, 2023
Last update
Feb 13, 2024

Study contacts

Alexandre Mebazaa, MD
principal investigator · Hôpitaux Universitaires Saint-Louis-Lariboisière, University Paris Diderot, Inserm 942

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion